FROM THE PRESIDENT

Rick Vulliet
prvulliet@ucdavis.edu

This is my first column as the incoming president of AAVPT and I am following in some very “big footsteps” of the previous office holders. To acquaint our newer members and remind others, the purpose of AAVPT is to promote the science of veterinary pharmacology and therapeutics. To accomplish this, the AAVPT is organized into various standing committees. Our committees are designed to represent all areas of veterinary pharmacology. If you are interested in participating in any of the committees, please visit the web site at http://www.aavpt.org, select a committee and either contact me or the soon to be named committee chairs (check the website frequently). Volunteers are always appreciated!

For members that were at the 15th biennial meeting at Asilomar, it was a tremendous success. We had 72 attendees from several different countries and program topics ranged from individualizing patient dosing to contemporary problems in veterinary pharmacology, such as antimicrobial resistance and veterinary compounding. From the depth and quality of the presentations, we identified several areas, such as veterinary compounding and antimicrobial usage that are currently being defined on a scientific basis. It is clear that we, as an organization, will have to develop carefully considered and well-reasoned positions in these areas. More on this later. At the meeting, we also gained several new members and I would like to welcome them aboard.

Lastly, I would like to thank the continuing and outgoing officers of AAVPT for a job well done. I think that the AAVPT is in as good as financial, organizational and political situation as I have ever seen it (and I have been a member since the founding meeting in Ft. Collins in 1978). This is a credit to the vision and guidance of these selfless volunteers who have dedicated numerous hours for the good of the organization. Due to the excellent stewardship of Jane Owens, past president, Joe Gloyd, secretary-treasurer, and the executive committee made up of Susan Longhoffer, Sanja Modric, Cyril Clark, Cynthia Cole, Jay Donecker, and Virginia Fajt we are a very sound organization. Debra Kochevar and Steve Sundlof finished at three year term on the EC this year and will be replaced by Ralph Claxton and Sherry Cox. I would also like to thank the members of the program committee for the 15th biennial meeting. Members of the program were Jane Owens, Carol Davis, Anthony Lucas, Susan Longhoffer, Marilyn Martinez, Linda Wilmot, Joe Gloyd and myself. I personally know the tremendous number of emails and early morning conference calls that putting this meeting together required.

We officers of AAVPT will do our best to serve you, but we are not mind readers. This is your organization! Please communicate with us. We are always looking for new ideas. Like most volunteer organizations, the more effort you put in, the more you will get out of AAVPT! I look forward to working with you during the tenure of my presidency.

OUTGOING- PRESIDENT’S REPORT

Jane G. Owens

Happy 30th Anniversary to AAVPT!

It was my honor and pleasure to serve as your president over these last two years. Thank you for the tremendous opportunity to lead such a great organization made up of so many talented colleagues and trusted friends. Going forward, my hope is to remain active in AAVPT and lead our efforts in establishing and funding a Veterinary Pharmacology Research Foundation.

I’m pleased to report that we are in the midst of a membership growth phase. In 06 we had the largest increase in our membership roles since the 70’s. My sincere hope is that this trend continues and that the organization is infused with new members who will lead us into our next 30 years. This growth is due in large part to the focused efforts of our revitalized membership committee under the able leadership of Carol Davis. These outreach efforts have been a key initiative of our...
organization and I’m very pleased to report that we are making measurable progress.

Financially, we are also doing well owing to the outstanding financial skills of our comptroller, Dan Gingerich. He has taken us from an initial investment of $34K in 1980 to $119K in 2007. I like to refer to Dan as the ‘AAVPT Rain Maker’. Our challenge now is to invest this money back into our mutual field of interest, veterinary pharmacology. This was the subject of a special session during the Biennial Symposium where we sought feedback from the membership on our plans for a Veterinary Pharmacology Research Foundation.

This year, I am pleased to announce that for the first time, we have awarded all of our organization’s honors under the able leadership of the Award Committee Chair, Anthony Luca. These awards included the AAVPT Service Award, Teaching Award and Research Award and our highest honor, the Lloyd E. Davis Award. These individuals have demonstrated outstanding leadership in our field and we benefit greatly from their work and dedication.

Our membership has been involved in an initiative to improve the quality of veterinary pharmacokinetic manuscripts which are published in our journal, JVPT. This effort is led by Marilyn Martinez of the FDA-CVM and includes members of the JVPT editorial board who represent AAVPT and our sister academy, EAVPT: Scott Brown, Johanna Fink-Gremmels, Peter Lees, Sanja Modric, Mark Papich, Jim Riviere, Stefan Soback and PL Toutain. The goal of this group is to increase the awareness, on an international basis, of appropriate study designs, methods of analysis, statistical concerns, assumptions, etc. associated with the analysis of pharmacological/pharmacokinetic datasets. Their plan is to have 1 or 2 editorials published in JVPT per year on these topics.

In early 2007, Virginia Fajt was instrumental in revitalizing the AAVPT website following council approval of an investment of approximately $5K. The majority of the past symposia proceedings have been posted on the AAVPT website (www.aavpt.org/symposia). If you happen to have a copy of the 1978 and 1980 proceedings, please contact Virginia Fajt

**Executive Council Update:**

Since the 2006 Annual General Meeting, the Executive Council has met by teleconference three times and has plans to meet at least quarterly to keep up the traction on our initiatives. We’ve made good progress on revitalizing several of our standing committees and we have nominated members to serve on several key US and Global committees that are vital to our membership.

Future items for the Council to consider include revising the AAVPT bylaws to extend the officer terms and split the secretary/treasure into 2 roles. These later changes will ensure that the organization has more focus, consistency and will hopefully reduce the ‘officer fatigue’ that commonly occurs in small volunteer organizations.

Two new councilors joined the Executive Council at the Annual General Meeting in May 2007: Anthony Lucas and Virginia Fajt. Steve Sundlof and Debbie Kochevar’s council terms expired just prior to the Annual General Meeting. Our thanks go out to Steve and Debbie for their excellent and longstanding contributions to Council.

**Current AAVPT Initiatives**

We have several initiatives that are centered on our organization’s Mission Statements:

1) Mission: support and promote education and research in veterinary pharmacology and to enhance the exchange of educational materials and ideas among veterinary pharmacologists

Current Initiatives Include:

- Increasing our recruiting efforts with a special focus on Veterinary Pharmacology Educators to facilitate collaboration among those teaching Pharmacology in Veterinary Schools
- Securing scholarship funds for Veterinary Students with interests in Pharmacology to ensure long term growth of the profession
- Securing grant money for comparative veterinary pharmacology research to increase the funding opportunities for basic research in veterinary pharmacology (see section on the Veterinary Pharmacology Research Foundation for more details)

2) Mission: organize committees of experts to research and make recommendations to the profession on current problems in veterinary therapeutics

Current Initiatives Include:

- Enhancing liaisons with American College of Veterinary Clinical Pharmacology, USP and AVMA
- Increase activity of the following committees: Awards, Education, Symposium Planning, and Membership Committees
- Sponsor and conduct workshops, symposia or other scientific and educational meetings in veterinary pharmacology and therapeutics.
Current initiatives and collaborations include:

AAVPT and ACVCP sponsored program sessions during the American College of Veterinary Internal Medicine Forum in Seattle Washington, June 6-9, 2007. (www.acvim.org). This was ACVIMs 25th Anniversary.

Committee and Liaison Responsibilities:

Current list of Committees and Members:

Bylaw’s Committee - Ted Whittem (Chair), Jane G. Owens

Membership Committee – Carol Davis (Chair), Jane G. Owens, Rob Hunter, Sanja Modric, Bernadette Dunham, Kirby Pasloske, Rainer Muser

JVPT Editor– Jim Riviere, Mark Papich

ACVCP Liaison – Debbie Kochevar

AAVPT Newsletter Committee - Cory Langston (Chair), Craig Parks

Awards Committee – Anthony Lucas (Chair), Jane Owens, Carol Davis, Rob Hunter, Eden Birmingham, Rick Vuillet

Education Committee – Cory Langston (Chair), Debbie Kochevar, Carol Davis, Rob Hunter*

2007 Program Committee – Rick Vuillet (Chair), Jane G. Owens, Sanja Modric, Cyril Clarke, Susan Longhofer, Anthony Lucas, Carol Davis, Cory Langston, Joe Gloyd and Marilyn Martinez

2006 Nomination Committee – Jane G. Owens (Chair), Joe Gloyd, Rick Vuillet

Finance and Budget – Dan Gingerich and Joe Gloyd

ACVCP/ACVIM Program Liaison – Jane G, Owens, Cory Langston

Drug Availability and Food Safety –Inactivated at EC Committee Meeting in May, 2005.

Long Range Planning Committee – Defunct. Executive Council assumes this charge

Exam Committee – Defunct owing to genesis of ACVCP

Monetary Gap: There are no dedicated research funds for basic or applied research in veterinary pharmacology. As such, researchers are drawn to other funding streams where the focus is on using animals as models for human disease rather than investigating the pathophysiology of animal diseases or discovering new therapies for medical conditions in veterinary species.

Expertise Gap: There are not enough veterinary pharmacologists in academia, industry or regulatory agencies. Academic pharmacology assistant or associate professor positions are often filled by PhDs who have very little veterinary training or interest in veterinary pharmacology research.

This proposal outlines a long range plan that seeks to fill these monetary and human resource gaps through collaborations between those most invested in veterinary pharmacology, AAVPT and ACVCP. Each of the following steps is designed to build upon the previous step with the first one being the simplest.

Step 1 – Reach Out to Veterinary Pharmacology Educators - Initiated 2006

Expand and enhance AAVPT/ACVCP Influence at US Veterinary Schools. The AAVPT Membership Committee has recently been revitalized and now includes two ACVCP members. This committee has been charged to recruit current veterinary pharmacology educators. This is a great opportunity for the AAVPT Membership and Education Committees to collaborate with the ACVCP Education
Committee to reach out to each US Veterinary School and get the people that are teaching pharmacology aware of the resources that our organizations can offer them.

Other actions include developing AAVPT and ACVCP brochures which we could also distribute at national veterinary meetings.

Impact: Increase communication between veterinary pharmacology researchers and increase AAVPT membership and interest in ACVCP by developing professional relationships with professors and their students

Step 2- Establish a Veterinary Pharmacology Research Foundation- Initiated 2006.

Establish a research foundation that is patterned after Morris Animal Foundation but will focus on funding research on comparative veterinary pharmacology. Solicit monies from several pharmaceutical companies who have veterinary divisions and employees involved AAVPT and ACVCP. Ask for their input into the organization’s mission statement and focus of research. Develop funding programs in conjunction with AAVPT Biennial Meetings to create incentives for sponsors to donate funds for meeting sponsorship and VPRF-driven research.

Impact: Grow the field of veterinary pharmacology by funding research programs designed to develop and validate models of animal diseases or conditions, evaluate safe and effective therapies for veterinary species and ensure the safety of the food supply.

Ideas for research focus: Use of human pharmaceuticals in veterinary species, objective models of animal diseases, animal pain control, etc.

In May 2006, both AAVPT and ACVCP governing bodies agreed to participate and sanctioned the organization of the foundation. We have contracted legal counsel and have incorporated the foundation. The attorney, John Thomas of Luman, Lange, Thomas & McMullen, LLP, Washington, DC, determined that AAVPT is classified as 501c6 professional society and as such has no income tax exemption to conduct a foundation under this corporation. He drafted new articles of incorporation for the foundation and they have been approved by the state of Illinois. AVMA is the registered agent for this foundation and we have appointed an interim board consisting of Joe Gloyd, Anthony Lucas and Jane Owens.

This was discussed at both the AAVPT and ACVCP Executive Councils at the Asilomar Conference Center during the Biennial Meeting in May 2007. Both organizations agreed to expand the interim board to include Dan Gingerich and Mark Papich. The first actions for this board will be to develop bylaws, elect officers (President, Secretary/Treasurer and if needed, a Vice President) and complete the 501c3 application. This application will include a summary of our plans for the foundation i.e., how it will be governed, fundraising plans and budget projections through 2009.

Ideas Generated During 15th Biennial Meeting At Asilomar:

Funding Sources
Solicit money from Sponsors of AAVPT Symposia – Develop a Program whereby they support the Symposia and donate money to the VPRF.
Solicit monies from pharmaceutical companies who have veterinary divisions and employees involved AAVPT and ACVCP
Initially partner with another research foundation such as ACVIM’s Foundation or Morris Animal Foundation until our funds are adequate to support a stand alone funding agency. Other funding sources considered: Wellcome Trust, Pew Foundation, Doris Duke Foundation, wealthy private citizens with animal health interests etc.
Solicit money or stock from retiring pharmacologists
Suggest that the grant money does not pay indirect costs or salaries (other than the student’s) so that funds are maximized towards research
Consider collaboration with EAVPT’s Foundation to fund travel grants for students to participate in research externships in EU laboratories.
Consider having ‘charter contributors or lifetime members’ who may donate money (> $5000) to join foundation
Solicit monies from AAVPT members directly when dues are collected.

Research Focus
Double-blind controlled clinical trials of veterinary therapeutics
PK/PD relationships
Population PK
Molecular Biology – comparative metabolism of P-450 enzymes among veterinary and zoo species

*In vitro – in vivo* efficacy correlations
Injection site residues
The effect of Breed/gender/physiologic differences on Efficacy/PK/Safety
Pharmacovigilance
Feline PK/metabolism
Issues related to compounding i.e., PK, product stability, safety, efficacy of compounded formulations

*In vitro – In vivo* modeling of drug dissolution in veterinary species
Treatments for diabetes, laminitis or other difficult diseases
Aquaculture
Efficacy of Transdermal formulations
Endotoxin sensitivity differences between species
Drug-Drug Interaction with Constant Rate Infusions of multiple drugs

Step 3 - Fund Summer Internships for Pharmacology Students – Initiate by 2008
Secure funds for summer internships for students with interests in pharmacology to ensure long term growth of the profession
Build upon Step 2 and grow the mission of VPRF to fund internships in addition to basic research.
Build on existing summer internship programs in the pharmaceutical industry, government and academia.

Impact: Increase the number of students interested in pursuing careers in pharmacology research

Step 4 – Fund ACVCP Residency Programs – Initiate by 2010
Secure funding for residency programs for ACVCP. The lack of funding for ACVCP training programs is the largest threat to the future of ACVCP. There exists a lack of qualified candidates who are board certified clinical pharmacologists to fill positions in industry, regulatory, and academia.

Build upon Step 3 and grow the mission of VPRF to pharmacology residency programs.

Impact: Insure the future of ACVCP and the supply of veterinary pharmacologists

**PRESIDENT-ELECT**

*Carol Davis*

I would like to sincerely thank you all for the support and electing me to serve as your next AAVPT president-elect. I am grateful for having this chance to serve our academy. I move into this office knowing I join a long list of outstanding veterinary pharmacologists who have served before me and want you to know I feel very privileged to be elected to this office. It is truly an honor to have the opportunity to contribute as an officer and I look forward to working with all the officers, counsel members and committee members during my term as your president-elect and into the future as become president.

The president-elect’s assigned duty is to serve as the chairperson of the Program Committee for all scientific sessions sponsored by the Academy. I have served on the last two biennial symposium program committees and have a good understanding of how these things are put together and hope to begin work on forming the 2009 16th Biennial Symposium program committee in the next couple of months. As in the past, it seems the last day of the 15th Biennial Symposium becomes the first day for planning for the next symposium. At the meeting in Asilomar it was agreed Drs. Mark Papich and Trish Dowling would serve on the committee as representatives from the ACVCP. I thank them for stepping forward to help with the program. This is one of the things I suggested in my platform statement – enhance collaboration between AAVPT and ACVCP and joint participation on the program is one way to foster this. I welcome their participation. To begin the planning, my first goal will be to get the venue set as early as possible and to look at the best time of the year so as not to run into other important meetings. We want to give our members a good lead time to plan for the meeting. A long term issue we have been asked to look at is how we might collaborate with the EAVPT and ACVCP and joint participation on the program is one way to foster this. I welcome their participation. To begin the planning, my first goal will be to get the venue set as early as possible and to look at the best time of the year so as not to run into other important meetings. We want to give our members a good lead time to plan for the meeting. A long term issue we have been asked to look at is how we might collaborate with the EAVPT and their meetings. This has always been problematic since we hold a biennial meeting and they hold one every three years. We will have a hard look at this and see if we can find ways we might collaborate.

As I stated in my platform, I have a concern that the amount of time taken up by program planning and what impact this activity has on the executive council’s ability to address other important activities. I really would like to
find ways to stabilize the symposium activity and institute a formal process for how we organize this meeting. I would like to develop some guidelines on how we lay out the meeting. This would help session chairs something to go by when trying to select speakers and topics. As an example, we might define a morning or afternoon session as a session with 4 invited speakers with a coffee break and panel discussion to be held within a four hour period. This would help us better plan and project costs for speakers. We might want to try having more roundtable or workshop sessions included along with more open time for visiting and sight seeing. I would love to have feedback on these ideas or get other ideas you might have on what YOU would like to see at our meetings.

Since we are not big enough to have paid staff we need to find ways to provide on-going continuity to our program responsibilities. We might try to set up some standard operating procedures to shorten the learning curve for incoming officers and to reduce the burden of program development on the officers. We definitely need to have a longer time frame for selecting where and where we hold our meetings and to try to find ways to control the costs of our meetings. We now have a very successful sponsor support program in place thanks to Dr. Anthony Lucas and have had excellent support from our sponsors for our last two symposia. I want to thank all our sponsors for their support of our programs. We simply would not be able to finance our meeting with out their support. Having a longer time frame should help in our sponsor program since sponsors would appreciate knowing well in advance in order to budget the sponsorship. But meetings simply are very expensive propositions. Timing of the meeting is very important but content still remains the most critical factor that determines whether a meeting succeeds or fails. This remains one of the greatest challenges for our organization.

We have a number of additional meetings that are being considered for this year and next. It should be a very busy time for all of us on the counsel. I am extremely optimistic about the vitality of the AAVPT and look forward to working with everyone in the academy. I invite any comments or suggestion on programming and would like to encourage you to send me any ideas you might have how we might structure the next meeting.

SECRETARY/TREASURERS
REPORT
Joe Gloyd

New Members
We continue to attract new AAVPT members. Since the fall ’06 newsletter we have three new fellows, nine new regular and four student members. They include Dominique Thibaud, Thomas Vickroy, Douglas Mouzin, Linda Rhodes, Glen Wolfrom, Levent Dirikloiu, Eduardo Gutierrez-Blanco, David Griffin, Lara Maxwell: all regular members. New Fellows include: Roger Jelliffe, Joanna Murrell, and Mathieu Peyrou, formerly a student member. The four new student members are Sandra McConkey, Brian Lubbers, Renata Linardi, and Mohammad Al-Bataineh. Incidentally, all the new student members attended the AAVPT Symposium, May 20-24.

As of June 15, there were 136 who had paid their 2007 AAVPT dues. Some 40 second notices were sent out recently. To date, about twenty-eight members have responded to the notice. Your secretary hopes that the other 12 members will respond soon. Dues may be paid by checks or credit cards, which may be sent by fax, email or even by telephone. Fax#302-761-9680; telephone 302-761-9690; email: aavptsec@aol.com or joegloyd@aol.com.

AAVPT Symposium
The 15th Biennial AAVPT Symposium took place on May 20-24, 2007 at the Asilomar Conference Center in Pacific Grove, California. Some seventy-six individuals attended the Symposium including seven from Canada and six from countries outside North America. Attendees enjoyed hearing twenty-two speakers covering topics such as animal pain control, individualizing treatment of patients, compounding in veterinary medicine, and antimicrobial resistance. Workshops on veterinary education and skills needed for employment in academia, animal health industry, and regulatory agencies were also presented as sessions in the program. In addition, sixteen posters and oral presentations by veterinary graduate students were included on the program’s third day.

Opening the program on the evening of May 20 was Dr. Stephen Sundlof, Director of the FDA Center for Veterinary Medicine, who charmed his listeners with some humorous and more serious aspects of the recent withdrawal of contaminated pet food by his agency. Symposium attendees stayed in Asilomar’s comfortable cabin residences without phones, TV, or other distractions. However, the main lodge did have wireless internet access. Early mornings, program breaks and late evenings usually found a goodly number of Symposium attendees crouching over their portable computers. Meals at Asilomar are served in a huge dining hall where Symposium registrants were assigned tables where they could share in conversations of mutual interest. The Conference Center has some 375 rooms in buildings scattered over a quarter-section, so the AAVPT Symposium was a small fraction of the ever-changing populace of Asilomar.
Symposium Sponsors

Success of the Symposium was dependent in a large part on the support of commercial sponsors. Gold sponsors of the event were Elanco, Merial, and Pfizer Animal Health. Silver sponsors included Avogadro, Bayer Animal Health, Dechra Pharmaceuticals, Idexx Pharmaceuticals, and Animal Pharm. Alchero Bio LLC and Schering-Plough Animal Health were Bronze sponsors.

Officer Elections

The results of voting on new officers for AAVPT were announced at the Annual General Meeting, which took place during the Symposium.

President Elect: Carol Davis
Secretary/Treasurer: Anthony Lucas
Councilors: Ralph Claxton, Sherry Cox

The term of office for the President Elect began immediately following the Annual General Meeting. Terms of newly elected Council members will not begin until after the 2008 Annual General Meeting and the Secretary/Treasurer’s term will begin January 1, 2008. Councilors are elected for three year terms, while the terms of office President and Secretary/Treasurer are two years. At the close of the General Meeting, President Jane Owens ‘passed the gavel’ to Richard (Rick) Vulliet who as President Elect was also Symposium Program Chairman.

Councilor Appointment

Prior to his election as Secretary/Treasurer, Anthony Lucas had been elected to a three year term as Councilor beginning in 2007. Therefore, he resigned the Councilor position and asked that someone be appointed to take his place. The Council then appointed John (Jay) Donecker to a two year term beginning in 2007. Dr. Donecker had been third in the voting for Councilor.

Awards Banquet

Highlighting the Symposium the evening of May 23 was the Award Banquet where winners were announced and awards presented. Only two of five awardees were able to attend the Symposium, but plaques and awards were presented to others by mail.

Service Award: Plaque and $500  Carol Davis and Cory Langston
Teaching Award: Plaque and $500  Jeff Wilcke
Research Award: Plaque and $500  Lauren Trepanier
LE Davis Award: Plaque and $750  Peter Lees

The two awardees present also received free registration, transportation and other costs of attending the Symposium.

Receiving the Service Award, Dr. Cory Langston was honored for his editorship of the AAVPT Newsletter, and service on the USP Expert Panel, the FDA Veterinary Advisory Committee, the AVMA Council on Biologic and Therapeutic Agents, and the American College of Veterinary Clinical Pharmacology.

Dr. Peter Lees, recipient of the LE Davis Award presented the LE Davis Lecture to banquet attendees. A world-renowned expert on control of animal pain, Dr. Lees is a professor of the Royal Veterinary College, University of London, Hawkshead Campus. He claims to be semi-retired but ‘keeps his hand in’ and is frequently called upon to share his knowledge about control of pain in animals. Punctuating a serious talk with humor and many quotes from Winston Churchill, Dr. Lees concluded by asking that his monetary award be considered as the first donation to the AAVPT Pharmacology Research Foundation.

ACVCP/AAVPT Resident/Graduate Student Pharmacology Research Award: Certificate and $1000.
Winner of the award was Dr. Chantal Lainesse who had competed with fifteen other entries, all of which were very good. Her poster, abstract and oral presentation was titled “In Vitro Metabolism of Clomipramine in Cats and Dogs: a Preliminary Comparative Study”. Dr. Lainesse is presently at the University of Montreal and resides at Markam, Ontario, Canada.

Financial Report AAVPT 15th Biennial Symposium

Overall, and thanks to our commercial sponsors, the Symposium was a financial success:

<table>
<thead>
<tr>
<th>Income:</th>
<th>$14,500 (another $3,475 is still to be collected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registrations</td>
<td>$18,400</td>
</tr>
<tr>
<td>Total</td>
<td>$32,900**</td>
</tr>
</tbody>
</table>
Expenses:
Speaker travel, lodging and honoraria: $18,132.32
Awards, Plaques, travel, registration: $4,361.16
(LE Davis, Research, and Student/Graduate)
Asilomar costs: $8,956.61
Total: $31,450.09
Net income: $1449.91*

($3,475 may be added)

* From Net income, $750 will be transferred to the AAVPT Pharmacology Foundation and another $60, which was subtracted from Dr. Murrell’s reimbursement, will pay her application and 2007 dues as a new AAVPT Fellow.

**Net income will be increased by $500 from the ACVCP share of the Student/Graduate Award.

Outgoing Officers
Terms of office expiring at the end of the Annual General Meeting were:
President: Jane Owens who will have a three year term as Past President and will serve as Chairman of the newly formed AAVPT Pharmacology Research Foundation.
Past President: Edward LB (Ted) Whitten
Councilors: Deborah Kochevar and Stephen Sundlof
Drs. Kochevar and Sundlof will continue in their respective day jobs as Dean of Tufts University School of Veterinary Medicine and Director of the Center of Veterinary Medicine, FDA.

AAVPT Pharmacology Research Foundation
In other action, the AAVPT Council appointed the following individuals as directors of the AAVPT Pharmacology Research Foundation: Jane Owens (Chair), Anthony Lucas, Dan Gingerich, Mark Papich, and Joe Gloyd. Prior to seeking funding for the Foundation, the directors will be responsible for writing bylaws and, with the assistance of attorney John Thomas of Washington, DC, attaining tax exempt status from the Internal Revenue Service.

AAVPT Website
The problems experienced last fall have been cleaned up and upgraded, thanks to our current webmaster at Texas A & M University. The membership directory can still be reached at http://www.avpt.org/member/admin. The user name is aavpt and the password is acadmem. (This should be ‘old news’ to those who regularly use the website.)

AAVPT Award Fund
At this point, 30 individuals have contributed a total of $1,701.00 to the award fund. That is considerably over the $730.00 we received last year. The amounts given ranged from $5.00 to $450.00. Many thanks to the 30 loyal AAVPT members who gave to the fund!

Listserv
In late 2006 and early 2007, the secretary/treasurer was notified that certain members in good standing were being deleted from the listserv. Attempts were made to place the email names back where they belonged. If you find that your email is not included on listserv, please notify the secretary/treasurer immediately.
### AAVPT Current Officers

<table>
<thead>
<tr>
<th>Office</th>
<th>Name</th>
<th>Address</th>
<th>Phone #</th>
<th>Fax</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Richard Vulliet</td>
<td>University of California School of Veterinary Medicine Dept. of Veterinary Molecular Biosciences Davis, CA 95616</td>
<td>530 752-7409 (Cell): 530 902-9007</td>
<td>530 752-7409</td>
<td><a href="mailto:prvulliet@ucdavis.edu">prvulliet@ucdavis.edu</a></td>
</tr>
<tr>
<td>President Elect</td>
<td>Carol Davis</td>
<td>Davis Consulting &amp; Training 410 Evergreen Court West Urbana, Illinois 61801</td>
<td>217 384-2860</td>
<td>217 384-6436</td>
<td><a href="mailto:carol.davis2@insightbb.com">carol.davis2@insightbb.com</a></td>
</tr>
<tr>
<td>Past President</td>
<td>Jane Owens</td>
<td>Elanco Animal Health 2001 W. Main Street Drop Code GL 36 Greenfield, IN 46140</td>
<td>317 276-1476</td>
<td>317 277-4993</td>
<td><a href="mailto:clarkjo@lilly.com">clarkjo@lilly.com</a></td>
</tr>
<tr>
<td>Secretary/Treasurer</td>
<td>Joe Gloyd</td>
<td>Gloyd Group 3 Penny Lane Court Wilmington, DE 19803-4023</td>
<td>302 761-9690</td>
<td>302 761-9680</td>
<td><a href="mailto:joegloyd@aol.com">joegloyd@aol.com</a></td>
</tr>
<tr>
<td>Secretary/Treasurer Elect 2008-2010</td>
<td>Anthony Lucas</td>
<td>Elanco Animal Health 2001 West Main Street PO Box 708 Greenfield, IN 46140</td>
<td>317 651-4371</td>
<td>317 277-4522</td>
<td><a href="mailto:lucasan@lilly.com">lucasan@lilly.com</a></td>
</tr>
<tr>
<td>Councilor 2005-2008</td>
<td>Susan L Longhofer</td>
<td>Dechra Pharmaceuticals 11 Yeomanry Road Battlefield Enterprise Park Shrewsbury, Shropshire UK SY1 3EH</td>
<td>44 1743 453 076</td>
<td>44 1743 462 120</td>
<td><a href="mailto:susan.longhofer@dechra.com">susan.longhofer@dechra.com</a></td>
</tr>
<tr>
<td>Councilor 2005-2008</td>
<td>Sanja Modric</td>
<td>Food &amp; Drug Administration FDA-CVM 7500 Standish Place HFV-135 Rockville, MD 20855</td>
<td>301 827-9382</td>
<td>301 827-4317</td>
<td><a href="mailto:smodric@cvm.fda.gov">smodric@cvm.fda.gov</a></td>
</tr>
<tr>
<td>Councilor 2006-2009</td>
<td>Cyril R. Clark</td>
<td>Oklahoma State University Center for Veterinary Health Sciences 205 McElroy Hall Stillwater, OK 74078-0353</td>
<td>405 744-8093</td>
<td>405 744-6633</td>
<td><a href="mailto:clarke@okstate.edu">clarke@okstate.edu</a></td>
</tr>
<tr>
<td>Councilor 2006-2009</td>
<td>Cynthia Cole</td>
<td>Idexx Pharmaceuticals, Inc. 4249 Piedmont Parkway Suite 105 Greensboro, NC 27410</td>
<td>336 834-6547</td>
<td>336 834-6525</td>
<td><a href="mailto:Cindy-Cole@idexxpharma.com">Cindy-Cole@idexxpharma.com</a></td>
</tr>
<tr>
<td>Councilor 2007-2010</td>
<td>John (Jay) Donecker</td>
<td>Pfizer Equine 707 Parkway Blvd. Reidsville, NC 27323</td>
<td>336 342-5093</td>
<td>866 590-0323</td>
<td><a href="mailto:john.donecker@pfizer.com">john.donecker@pfizer.com</a></td>
</tr>
<tr>
<td>Councilor 2007-2010</td>
<td>Virginia Fajt</td>
<td>Texas A&amp;M University Dept.of Veterinary Physiology and Pharmacology College of Veterinary Medicine College Station, TX 77843-4466</td>
<td>979 845-7299</td>
<td></td>
<td><a href="mailto:vfajt@cvm.tamu.edu">vfajt@cvm.tamu.edu</a></td>
</tr>
<tr>
<td>Councilor 2008-2011</td>
<td>Sherry Cox</td>
<td>University of Tennessee College of Veterinary Medicine Knoxville, TN 37996-4543</td>
<td>865 974-5646</td>
<td>865 974-5640</td>
<td><a href="mailto:scox6@utk.edu">scox6@utk.edu</a></td>
</tr>
</tbody>
</table>

**Note:** Officer terms begin at the Annual General Meeting of the first year of service and end just prior to the Annual General Meeting of their last year of service. One exception is for the Secretary/Treasurer whose term begins and ends on a calendar year cycle. The term for the Secretary/Treasurer starts in January of the year following the election. Committee and Liaison Responsibilities: (To be renamed soon by Rick Vulliet)
MEMBERSHIP COMMITTEE
Carol Davis

The membership committee had one major project this past year – recruitment of new members at veterinary schools in North America and Australia/New Zealand. Our goal was to try to have at least one AAVPT member at every school in the United States. To begin, we first created a list of all the veterinary schools and collected contact information for people we thought we might contact. Our final list included - 8 schools in Australia/New Zealand, 28 in US, and 4 in Canada. Each committee member was assigned 4 or 5 schools. Each of us was to contact the assigned schools, give them some background about our organization and invite them to become a member. We have spent the last few months following up on our assignments.

One observation that seemed to come up when we searched through the various school websites which might warrant further study by our committee or EC. At the start it was somewhat problematic when we tried to find who taught the courses in pharmacology at some of the schools. We could not always find pharmacology listed as an administrative unit. It appears that over the years many schools have reorganized their departmental structures or changed the names of their administrative units which made it difficult to immediately locate pharmacology units or divisions at some of the sites. It took some searching to identify who was teaching pharmacology. They did not always have pharmacology listed as their main area of research. It is still apparent that pharmacology is still being taught but I have the impression although some of the faculty has responsibility for these courses but they are not necessarily developing or focusing on research programs in what we might describe as veterinary pharmacology. This might be why they are not members of AAVPT. It could be as simple as they just do not know about AAVPT or they do not see the benefit of AAVPT membership in their research activities. We need to be more creative in finding ways to make membership in AAVPT more valuable to these individuals. This is one area where the education committee and the membership committee can and should be working together. One thing is apparent to me. We need to find ways to highlight AAVPT or give our group better exposure at some of the veterinary schools. It is apparent that some of the people we contacted did not know anything about our organization. Although we have invited many of them to join, we still need to review our results and see if there are others we should contact to extend an invitation. Maybe we could develop a newsletter or periodical mailing to selected individuals to inform them of our activities and keep them aware of some of the important issues facing us.

To summarize where we stand - most of the schools have been contacted and we have had some success in finding new members. In reviewing Joe Gloyd’s membership list, I found we received 26 new members in 2006 and 2007 (7 fellows, 11 regular and 7 student members) - 13 are in academia, 8 in industry, 4 are students and 1 is in private practice. Although we have 13 new members in the academic category, we have not reached our goal. Of the 13 new academia members, only 2 are from schools we were targeting. There still are about 8 schools we need to follow up on to get closer to our goal of having at least one AAVPT member at each school.

I would again like to thank the committee members for all their help this year. The members are Bernadette Dunham, Kirby Pasloske, Sanja Modric, Rob Hunter, Virginia Fajt, Jane Owens and Rainer Muser. The committee will continue with the same goal and will expand our efforts to include the regulatory sector. I invite anyone interested in joining our committee to please contact me or anyone on the committee.

AWARDS COMMITTEE
Anthony Lucas

For the first time ever, all of the AAVPT awards have been presented in the same year. The awards were presented at the 15th Biennial Symposium at the Asilomar in California on May 21 – 24, 2007.

The Lloyd E. Davis Award, for significant contributions to the advancement and extension of knowledge in veterinary or comparative pharmacology, was presented to Professor Peter Lees.

The AAVPT Service Award, to recognize significant service to the fields of veterinary or comparative pharmacology, or therapeutics, was co-awarded to Carol Davis and Cory Langston.

The AAVPT Teaching Award, to recognize significant teaching activities in the fields of veterinary or comparative pharmacology, or therapeutics, was awarded to Jeff Wilcke.

The AAVPT Research Award, to recognize significant research contributions to the fields of veterinary or comparative pharmacology, or therapeutics, was awarded to Lauren Trepanier.

Congratulations to all of the Awards recipients.

Thanks also to Robert Hunter for his assistance with the awards committee.
JVPT continues to thrive in its new on-line home. Of great significance, JVPT has increased its Impact Factor yet again, now to 1.406 which ranks us as 22/128 Veterinary Journals (last year: 1.294; 24/129). This continued growth is based on the outstanding papers submitted coupled with the outstanding work of our Editorial Board members and reviewers. Manuscript submissions have doubled in 2006 over 2007, allowing us to publish a wider variety of high quality manuscripts. The turnaround time from submission to decision is also significantly shortened compared to the old paper system. We will be publishing a reviewed supplement this year covering the pharmacology and safety of a new approved drug. This is the first for JVPT and if successful, might prove a useful venue to get the science out on new compounds in a peer-reviewed format. We continue to need comprehensive review articles that cover issues of importance to veterinary pharmacology, therapeutics and toxicology. Should you have any ideas, please develop them and pass them to our review editor Dr. Mark Papich.

I close this report on a sad note. In December of last year, a long-time member of our editorial board, Dr. Des Hennessy of Australia unexpectedly died in a gliding accident. Des was an internationally recognized pharmacologist widely known for his work with antiparasitics. I will miss his critical reviews if articles in this area.

LIAISON REPORTS

Food and Drug Administration

Stephen F. Sundlof

CVM Approves Important Drugs for Use in Aquaculture

Under provisions of the Minor Use and Minor Species Act (MUMS Act) of 2004, the Center for Veterinary Medicine this year approved two important aquaculture drugs and granted one of the drugs an additional much-needed and first-ever “conditional approval.” The products were all aided by the fact they received designation status under MUMS.

A drug sponsor can apply to CVM to have a drug given designation status under the MUMS Act prior to the drug’s approval or conditional approval. Designation status provides benefits to drug sponsors to encourage them to develop drugs for minor uses and minor species. (Aquaculture species are considered minor species.) Sponsors who gain approval for designated new animal drugs will be granted 7 years of exclusive marketing rights for the approved drug and indications, which means the sponsor will face no competition in the marketplace for the approved use of the drug for that time period.

Without the designation status, an approved new chemical entity receives only 5 years of protection, and a supplemental approval gets only 3 years protection.

Conditional approval provisions of the MUMS Act allows the sponsor to market a drug for certain indications before collecting all necessary effectiveness data. CVM will grant a conditional approval for drugs meeting target animal, environmental, and food safety requirements, and in cases in which CVM anticipates that the sponsor will be able to collect all effectiveness data. The sponsor can market the drug for up to 5 years, with annual renewals, under a conditional approval.

Eka Chemicals, Inc., Marietta, GA, taking advantage of the MUMS Act, has used data developed through an aquaculture drug public partnership to gain approval of 35% PEROX-AID®. The drug’s active ingredient is hydrogen peroxide. 35% PEROX-AID was approved for the control of mortality in:

- Freshwater-reared finfish eggs due to saprolegniasis;
- Freshwater-reared salmonids due to bacterial gill disease associated with Flavobacterium branchiophilum; and
- Freshwater-reared coolwater finfish and channel catfish due to external columnaris disease associated with Flavobacterium columnare (Flexibacter columnaris).

Bacterial gill disease and external columnaris disease are significant hatchery diseases, and 35% PEROX-AID is the first drug approved to treat these diseases.

Eka Chemicals leveraged data generated in the public sector to demonstrate the safety and effectiveness of hydrogen peroxide.

This approval is the first original drug approval with multiple claims encompassing a variety of finfish species and life stages. Eka Chemicals has 7 years exclusive marketing rights on each of the approved claims.

Another designated aquaculture product CVM has approved is AQUAFLOR® (florfenicol) Type A medicated article for the control of mortality in freshwater-reared salmonids due to coldwater disease associated with Flavobacterium psychrophilum. The sponsored is Schering-Plough Animal Health Corporation, Summit, N.J.
The drug – the first CVM has approved for use during coldwater disease outbreaks – is an important disease management tool for aquaculture and fisheries programs. Coldwater disease is an acute septicemic infection occurring primarily in salmonid fish species. The agent, *F. psychrophilum*, is a serious salmonid pathogen in the United States. The disease causes significant losses of hatchery-reared salmonids. Up to 50% of affected fish may be lost during disease outbreaks, with greater mortality in younger fish.

CVM approved AQUAFLOR Type A medicated article as a Veterinary Feed Directive drug, which means that the medicated feed can be used only on the order of a licensed veterinarian. The extralabel or off label use of medicated feed containing florfenicol is not allowed.

AQUAFLOR, an antimicrobial, was reviewed under the CVM’s Guidance for Industry, “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern.” The guidance provides a regulatory pathway sponsors can use to show how an antimicrobial drug can be used in food-producing animals without endangering public health.

The approval of AQUAFLOR is the result of cooperation between the pharmaceutical company sponsor and public sector researchers.

CVM also granted Schering-Plough conditional approval of AQUAFLOR-CA1 (the CA stands for conditional approval, and the 1 signifies this is the first for this formulation), also a Type A medicated article, for control of mortality in catfish due to columnaris disease associated with *Flavobacterium columnare*. The conditional approval will be important for the catfish industry because columnaris disease is estimated to cause up to 25% of disease losses in catfish annually.

**Expansion of Phish-Pharm**

Dr. Renate Reimschuessel of CVM’s Office of Research reports that the searchable fish pharmacokinetics database she developed, called “Phish-Pharm,” has been expanded to include approximately 430 articles, up from the 400 or so when it was first introduced in 2005 in an article in the *American Association of Pharmaceutical Scientists (AAPS) Journal*.

The database is a valuable resource to investigators of drug metabolism in aquatic species, and to government and private organizations involved in the drug approval process for aquatic species.

The database is available at [http://www.aapsj.org/view.asp?art=aapsj070230](http://www.aapsj.org/view.asp?art=aapsj070230), and can be viewed in an Access or Excel format, or as a stand alone application.

It has data derived from various articles covering 124 aquatic species (95 genera). Data fields include genus, species, water temperatures, the average animal weight, sample types analyzed, drug (or chemical) name, dosage, route of administration, metabolites identified, method of analysis, protein binding, clearance, volume of distribution in a central compartment (Vc) or volume of distribution at steady-state (Vd), and drug half-lives (t½). Additional fields list the citation, authors, title, and Internet links.

The database will be periodically updated, and users are invited to submit additional data. Additional updates will be announced in future issues of the *AAPS Journal*.

**American College of Veterinary Clinical Pharmacology**

*Debbie Kochevar*

The ACVCP has had a successful year that included renewal of its status as a fully certified college through the American Board of Veterinary Specialties, addition of two new diplomates and approval of one new training program (as of May 2007).

We welcomed the following new diplomates and look forward to their active involvement in the college: Alan Chicoine and Chantal Lainesse.

Approved ACVCP training programs and their supervisors include: a new program at Kansas State University (M. Apley) and existing programs at North Carolina State University (M. Papich), University of Wisconsin (L.Trepanier), Western College of Veterinary Medicine (T. Dowling), University of Montreal (M. Doucet), Iowa State University (Open).

New ACVCP officers (2007- 2009) are: President: M. Apley; President Elect: L.Trepanier; Vice-President: V. Fajt; Secretary-Treasurer: A. Boeckh; Past President: D. Kochevar.

Scientific Program Committee Chair, Dr. Mike Apley, working with both ACVCP and AAVPT programming committees developed a highly successful program for the ACVIM Forum in Seattle in June 2007. The program focused on evidence-based comparisons of traditional and newer therapeutic options for endocrinopathies, cancer, and renal, neurological, skin and cardiac disease. Science-driven design of dosing regimens was also addressed.

The ACVCP annual business meeting attracted a record 22 attendees and all appreciated the beautiful venue at the AAVPT Biennial Symposium in Asilomar, CA. Thanks to
Rick Vuillet and Jane Owens for doing a great job of organizing the symposium this year.

Notable business for the year included revision of the bylaws to provide for electronic balloting for consideration of dues increases and robust discussion of how best to manage quorum size to allow for conduct of college business.

Committee chairs M. Heit (Exam Committee) and M. Doucet (Credentials Committee) continued to upgrade and fine-tune web-based elements of their activities. Dr. Jeff Wilcke’s talents, as always, were essential to continued improvements in these areas. With Dr. Wilcke’s support, further enhancements in electronic college communications are in the works.

Several ideas were also presented to enhance training experiences for ACVCP residents using information technology tools. These included threaded discussions and desk top sharing in a rounds or journal club format.

AVMA COBTA
Cory Langston

ADUFA

The Animal Drug User Fee Act (ADUFA) is being reviewed for reauthorization as its October 1, 2008 expiration date approaches. AHI is evaluating whether the program is meeting its objective of decreasing time to market for new products, but in general, is relatively positive about the program. Some members of COBTA expressed concern that the fees represent a barrier to innovation by some small manufacturers. CVM held a public meeting in April 2007 on what the FDA should consider in the reauthorization process. The issue will be readdressed at the COBTA meeting in October 2007.

Therapeutic Diets

COBTA is concerned that therapeutic claims on pet food are largely unregulated. AVMA-COBTA will host a Therapeutic Pet Food Label Claims meeting at AVMA headquarters in October and invite key stakeholders in the pet food industry with an interest in the therapeutic diets issue. It is hoped that this meeting will give participants an opportunity to share their views.

FARAD Loses Funding

FARAD did not receive any funding in the 2007 budget passed by Congress and is now closed. The CPAC and COBTA were greatly dismayed by this information and believe FARAD is an invaluable resource to the veterinary medical profession as well as many others. It is the single most important source of extralabel drug use withdrawal interval information necessary to ensure food safety.

The COBTA approved a motion to recommend to the Legislative Advisory Committee (LAC) that the AVMA actively pursue permanent funding of FARAD.

NEWS

Jim Riviere Receives Honorary Degree

This article recently appeared in a Purdue University publication

Dr. Jim Riviere has distinguished himself as an international authority on comparative pharmacokinetics and toxicokinetics.

He is employed at North Carolina State University as the founding director of the Center for Chemical Toxicology Research and Pharmacokinetics in the College of Veterinary Medicine and has recently served as the director of the Biomathematics Graduate Program for the College of Physical and Mathematical Sciences. He lives in Raleigh, N.C.

Born and raised in New Bedford, Mass., Jim earned both his bachelor's and master's degrees from Boston College in the early 1970s before coming to Purdue as a teaching assistant in veterinary pharmacology, while pursuing his doctoral degree. He also worked as an extern at Eli Lilly's Toxicology Research Lab and received his D.V.M. and Ph.D. in pharmacology from Purdue in 1980.

Dr. Riviere left Purdue in 1981 to become an assistant professor of pharmacology and toxicology at N.C. State, where he also was a member of the graduate toxicology faculty for nine years.

He also was co-founder and co-director of the Food Animal Residue Avoidance Databank, a program that achieved permanent authorization by the United States Congress in 1998 and was recognized in 2001 by the Food and Agricultural Organization (FAO) of the United Nations.

Dr. Riviere's expertise has been recognized by his election to the Institute of Medicine of the National Academy of Sciences in 2003. Most recently he received the 2006 Lifetime Achievement Award from the European Association for Veterinary Pharmacology and Toxicology.

He has received many other prestigious awards. Two of his research contributions were identified by the NCSU News Services among the 100 greatest NCSU Achievements of the 20th Century.

As a scientist, Dr. Riviere's reputation is unparalleled in his field. He has published more than 400 peer-reviewed
manuscripts and 10 books, while also obtaining numerous patents and registered copyrights. He has also received more than $16 million in sponsored research funding at NCSU.

**Tom E. Powers Endowed Chair Announced**

This article recently appeared in an Ohio State University publication.

If you want to show a favorite professor that you care, you could send a card. Dr. Joe McCracken, however, decided that wasn’t quite enough. McCracken, of San Mateo, Calif., has given $875,000 to the College of Veterinary Medicine to create the Powers Endowed Chair in Clinical Pharmacology in honor of Dr. Thomas E. Powers, professor emeritus and former chair of the Department of Veterinary Physiology and pharmacology. “He was my mentor and a friend and just a really cool guy who has dedicated his life to public service, the university and to veterinary medicine,” said McCracken, who studied with Powers and worked with him in the lab as both an undergraduate and a graduate student in the late 1970s.

The two have exchanged Christmas cards and visited occasionally since McCracken graduated in 1980, and he stopped by to see Powers last fall after the Northwestern game. It was then that he remembered a small fund had previously been established in honor of his former professor. “I thought, if Tom is going to have an opportunity to receive the recognition he deserves, we should do something now so he can enjoy it,” he said. McCracken calls his former professor a pioneer in studying the use of drugs in animals. “It was Tom Powers in the 1970s who was largely responsible for bringing the principles of modern clinical pharmacology to veterinary medicine,” he said. Powers and his wife, Jean, also a professor emeritus in veterinary medicine, have added $100,000 of their own to the new fund. “I called them to tell them what the plan was,” McCracken said. “I told them, ‘I’m not calling to twist your arm, but I want you to know there is going to be an endowed chair in Dr. Tom’s name and I don’t want you to feel excluded.’ They called me back and said they wanted to contribute too.”

“We are very excited about the Powers Chair,” said Dr. Tom Rosol, dean of the College of Veterinary Medicine. “This endowment will help to raise the level of clinical pharmacology research at the college and will make a real impact on the health and well-being of animals. Tom has always cared a lot about students and about animals, and he dedicated his life to teaching pharmacology and expanding our knowledge of drug use in animals,” said McCracken. “I’m happy he can be recognized for that. It’s a wonderful thing.”

**2007 Raleigh Pharmacokinetic Workshop**

Mark Papich and Jim Riviere

October 11-13, 2007 This basic and practical workshop on comparative and clinical pharmacokinetics is in its fifth year and was also presented on-site to the FDA Center for Veterinary Medicine in 2006 and 2007. Course content is practical and relevant to the development and judicious use of therapeutic substances in animals. Full details and registration information can be found at WWW.KINETICWORKSHOP.COM

**DRUG & BIOLOGIC APPROVALS**

**Pimobendan (Vetmedin®) for Heart Failure In Dogs**

VETMEDIN (pimobendan) Chewable Tablets filed by Boehringer Ingelheim Vetmedica, Inc. Pimobendan in dogs is approved for the management of congestive heart failure due to atrioventricular valvular insufficiency or dilated cardiomyopathy. Pimobendan functions as a positive inotrope as well as an afterload reducer.

**Canine Melanoma Vaccine**

The USDA-APHIS issued a conditional license to Merial, Inc., of Athens, Ga., for a melanoma vaccine to aid in the treatment of oral melanoma in dogs.
The vaccine has been shown to aid in cancer treatment for dogs and has demonstrated a reasonable expectation of efficacy to increase the survival time of dogs with oral melanoma. This vaccine is approved for treatment of dogs with stage II or stage III oral melanoma in cases in which the disease has been contained.

CVM Working To Address Concerns About Supplies Of Pergolide for Horses

Pergolide, a drug used to manage the signs and symptoms of Parkinson’s disease in humans, is being removed from the market due to concerns about cardiac side effects.

CVM recognizes that veterinarians are prescribing pergolide, under AMDUCA guidelines, for the treatment of Cushing’s Syndrome in horses.

FDA is working with the sponsors of the approved products and all other interested parties to ensure that pergolide remains available to treat Cushing’s Syndrome in horses until a new animal drug application is approved for that use. This includes trying to make the approved product available through veterinary distribution channels and exercising enforcement discretion as appropriate over the pharmacy compounding of pergolide.

CVM will also work with sponsors who are interested in seeking approval of a new animal drug application for the use of pergolide to treat Cushing’s Syndrome in horses.

Maropitant (Cerenia®) – New Antiemetic In Dogs

CERENIA™ (maropitant citrate), filed by Pfizer, Inc. Maropitant injectable solution is approved for use in dogs for the prevention and treatment of acute vomiting. Maropitant citrate tablets are approved in dogs for the prevention of acute vomiting and for the prevention of vomiting due to motion sickness. The drug is the first neurokinin 1 (substance P) receptor antagonist approved in veterinary medicine.

Fluoxetine (Reconcile®) in Dogs

RECONCILE® (fluoxetine hydrochloride) Chewable Tablets, filed by Elanco Animal Health, is used for the treatment of canine separation anxiety in conjunction with a behavior modification plan. Fluoxetine is a selective serotonin inhibitor approved in humans as Prozac®.

Dirlotapide (Slentrol®) For Appetite Control In Overweight Dogs

SLENTROL (dirlotapide) Oral Solution, filed by Pfizer, Inc. is approved for the management of obesity in dogs. Dirlotapide is a selective microsomal triglyceride transfer protein (MTP) inhibitor. It is believed that this inhibition of MTP interferes with the packaging of digest fat into chylomicrons and an increase in fat within the intestinal cell. This increase in intestinal cell lipid triggers a decrease in appetite.

Dexmedetomidine (Dexdomitor®) – α2 Inhibitor in Dogs

DEXDOMITOR (dexmedetomidine hydrochloride), filed by Orion Corp, is an injectable solution used as a sedative, analgesic, and pre-anesthetic in dogs.

POSITIONS AVAILABLE

Merial R&D Leader (Director)

Duluth, GA, USA. Position is responsible for planning and supervising research projects on a national and international scale. Projects may involve research, pre-development, or development product candidates. Projects may involve single or multiple claims in one or more countries and several species of animals. May supervise others (e.g., Research Coordinators/Biostatisticians) assigned to the projects. Required travel on company business about 20% of the time.

KNOWLEDGE AND SKILLS: Minimum: DVM (or equivalent) and 6 years of experience in a field of veterinary medicine. Preferred: DVM (or equivalent) plus MS and/or PhD and 3 years of experience in a field of veterinary medicine. Solid working knowledge of basic science and the drug development process.

TYPE OF EXPERIENCE: Basic or clinical research in a pharmaceutical-related industry/university/institutional research setting. Resource and financial planning of complex projects are desired.

If interested, please apply at the Merial Web Site (www.merial.com), under ‘Careers’ / R&D.

Virbac R&D Manager

Fort Worth, TX. This Manager is a hands-on position, which must be able to strategize, plan, coordinate and execute present and future activities of cross functional teams of professionals. Travel is predominantly within the
US, with some Canadian and European potential; normally 10-30%, with periods as much as 50%.

TRAINING AND EDUCATION: MS, DVM, or PhD in a Science Curriculum. Training and knowledge of regulations needed regarding the use of animals in research, Good Clinical Practices, Good Laboratory Practices, a working knowledge of CFRs relevant to FDA/CVM and EPA, and project management experience.

Contact: Carol Buys-Michela; VP, Human Resources; 3200 Meacham Blvd; Fort Worth, TX  76137; 817-831-5030

AAVPT Newsletter
Editors: Cory Langston and Craig Parks
The Newsletter is published twice yearly by the American Academy of Veterinary Pharmacology and Therapeutics. Please kindly address all correspondence to:
Dr. Cory Langston
College of Veterinary Medicine
PO Box 6100
Miss. State, MS 39762-6100
USA
email: langston@cvm.msstate.edu